I have about 24 years of experience in studying the clinical effects of transcranial electric stimulation (TES) for treating symptoms of alcohol abstinent syndrome and narcomania.
My cooperation with Professor V. P. Lebedev and Dr. Ya. S. Katsnelson, the developers of this new TES method, began in 1983. This method is based on the use of quasi-resonance characteristics of an electric signal, that, in particular, activates the endorphinergic structures in the brain. The many years (over 10) of collaboration between Professor Lebedev and Dr. Katsnelson in co-authorship with other researchers was reflected in their receiving a number of USSR Inventor's Certificates and writing of numerous publications. The TES program that was developed by Professor Lebedev and Dr. Katsnelson in co-authorship with other researchers was used by Professor Lebedev to produce equipment for TES that is manufactured by his company.
Up until 1991, in cooperation with Professor Lebedev and Dr. Katsnelson, I conducted clinical studies whose innovation was confirmed by the awarding to us and a number of other coauthors of a USSR Inventor's Certificate; the results of these studies were published in coauthorship with other researchers, both in Russian and foreign publications.
During our collaboration, I developed the impression of Dr. Katsnelson as a highly skilled scientist and physician. I was very interested in reading his dissertation in 1985 for defense of the competition for scientific degree of Candidate of Medicine. Professor Lebedev, as one of the scientific leaders of the dissertation, was very positive about it and even recommended it for defense of the competition for scientific degree of Dr. of Medicine (Russia has adopted a two-tier gradation of scientific degrees: Candidate of Science is equal to PhD and Dr. of Science).
Even with all the clinical effectiveness of the TCS devices manufactured by Professor Lebedev's company, they still have certain shortcomings manifest as unpleasant sensations under the electrodes, sometimes burns. Other shortcoming may also include the use of re-usable electrodes and re-usable liners for them. All of this to a certain degree restricts the use of these instruments for broad clinical practice. It should be noted that the presence of sensations under the electrodes prevents the optimum studies using the double blind placebo controllable method.
In 2005, Dr. Katsnelson, as the medical director of Kalaco Scientific, Inc., approached me with a proposal to participate as the Chief Researcher in conducting pilot clinical studies to investigate the possible use of devices for transcranial electric stimulation NEXALIN to copy the symptoms accompanying Parkinson's disease. Recalling our previous collaboration, I was happy to accept this proposal.
These pilot studies have currently been completed. The positive results are the grounds for developing a system of using the NEXALIN devices for comprehensive Parkinson's disease therapy. In addition to the clinical effect, the positive features of the NEXALIN devices should include the absence of any sensations under the electrodes and the use of disposable electrodes.
Kalaco Scientific, Inc. is currently conducting double blind randomized studies to investigate the possible use of two modifications of the NEXALIN devices to treat depressive states of medium and light degree of severity. I again participated in them as the chief researcher. It should be noted that the studies are being conducted in strict compliance with the requirements of the Helsinki agreement, Russian Ministry of Health Care and Social Development, FDA, GCP and principles of demonstrative medicine.
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